Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MTNR1A | P48039 | 7/20 | 0.45 |
| ▸ | MTNR1B | P49286 | 7/20 | 0.45 |
| ▸ | CCR5 | P51681 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4629636 | 1.00 | LMNA (0.54) | LMNAALDH1A1KMT2ASMN1; SMN2MTNR1A | |
| SCHEMBL4629634 | 1.00 | LMNA (0.54) | LMNAALDH1A1KMT2ASMN1; SMN2MTNR1A | |
| SCHEMBL7733842 | 0.88 | ALDH1A1 (0.69) | LMNAALDH1A1KMT2ASMN1; SMN2MTNR1A | |
| SCHEMBL13996050 | 0.88 | ALDH1A1 (0.69) | LMNAALDH1A1KMT2ASMN1; SMN2MTNR1A | |
| SCHEMBL186238 | 0.80 | LMNA (0.61) | LMNAALDH1A1KMT2ASMN1; SMN2TDP1 | |
| SCHEMBL186416 | 0.80 | LMNA (0.61) | LMNAALDH1A1KMT2ASMN1; SMN2TDP1 | |
| SCHEMBL8582093 | 0.80 | RIPK1 (0.61) | LMNAKMT2ASMN1; SMN2 | |
| SCHEMBL607611 | 0.80 | RIPK1 (0.61) | LMNAKMT2ASMN1; SMN2 | |
| SCHEMBL186230 | 0.80 | LMNA (0.61) | LMNAALDH1A1KMT2ASMN1; SMN2TDP1 | |
| SCHEMBL607610 | 0.80 | RIPK1 (0.61) | LMNAKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070123589-A1 | Method for producing chiral or enantiomer-enriched beta-amino acids, aldehydes, ketones and gama-amino alcohols | DSM FINE CHEMICALS AUSTRIA NFG GMBH & CO KG (AT) | 2007-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123589-A1 | Method for producing chiral or enantiomer-enriched beta-amino acids, aldehydes, ketones and gama-amino alcohols | GLRA1, GLRB, GLRA2 | LMNA 2937/4885ALDH1A1 97/4885KMT2A 1115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.